Oxford Nanopore Technologies plc, trading under the symbol ONTTF on the OTC exchange, is a company known for its innovative DNA sequencing technology. On September 2, 2025, ONTTF reported its earnings before the market opened. The company posted an earnings per share (EPS) of -$0.1029, which was slightly better than the estimated EPS of -$0.1043. This indicates that the company's performance was marginally better than analysts had anticipated.
The company's actual revenue was approximately $145 million, surpassing the estimated revenue of around $143 million. This revenue growth is part of a broader trend, as highlighted by the company's first-half 2025 revenue of £105.6 million, marking a 25.6% increase from the previous year. The growth was driven by strong performance across all regions, with the APAC region leading at a 38.3% increase on a constant currency basis.
Despite the positive revenue figures, ONTTF experienced a 2.9% decline in its share price. This decline occurred even though the company reported a smaller-than-expected first-half loss and reaffirmed its full-year and medium-term outlook. The adjusted EBITDA losses were reduced to £48.3 million from £61.7 million the previous year, and the net loss decreased to £71.8 million from £74.7 million, indicating effective cost control.
The company's financial ratios provide further insight into its current financial health. ONTTF has a price-to-earnings (P/E) ratio of approximately -9.66, indicating negative earnings. However, the price-to-sales ratio of about 8.27 suggests that investors are willing to pay $8.27 for every dollar of sales, reflecting confidence in the company's revenue-generating potential. The debt-to-equity ratio of about 0.078 indicates a relatively low level of debt compared to its equity, while a current ratio of approximately 4.66 shows strong liquidity.
